Five minutes with…Sophie Humbert of cermaVEIN
This article was originally published in Clinica
Executive Summary
Freshly spun out of its parent company cerma, cermaVEIN last month joined the 18,000-plus SMEs that make up 80% of Europe's medtech industry. The French firm's focus is to commercialise its Steam Vein Sclerosis (SVS) system, designed to treat varicose veins in a minimally-invasive outpatient procedure. CEO Sophie Humbert discusses the advantages of the technology over its rivals, and overcoming the challenges of being a start-up